Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27581859 | 0.91 | DPP4 (0.38) | DPP4MAOBSGMS1SGMS2EDNRA | |
| SCHEMBL5236115 | 0.91 | DPP4 (0.43) | DPP4MAOBEDNRAACHEKCNH2 | |
| SCHEMBL6106224 | 0.89 | DPP4 (0.38) | DPP4MAOBSGMS1SGMS2EDNRA | |
| SCHEMBL5234336 | 0.88 | DPP4 (0.42) | DPP4MAOBSGMS1SGMS2 | |
| SCHEMBL5235861 | 0.87 | DPP4 (0.50) | DPP4MAOBSGMS1SGMS2 | |
| SCHEMBL5239247 | 0.86 | DPP4 (0.42) | DPP4MAOBEDNRAHRH3 | |
| SCHEMBL5234724 | 0.84 | DPP4 (0.44) | DPP4MAOBEDNRAHRH3 | |
| SCHEMBL6106223 | 0.84 | DPP4 (0.41) | DPP4MAOBSGMS1SGMS2EDNRA | |
| SCHEMBL5239033 | 0.83 | DPP4 (0.42) | DPP4MAOBHRH3 | |
| SCHEMBL27581917 | 0.83 | DPP4 (0.40) | DPP4EDNRAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885MAOB 1281/4885SGMS1 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.